tbuckley/cabot-search huggingface dataset:
Abstract 10364: Tight Systolic Blood Pressure Control With Combination Therapy Decreases Type 2 Endoleaks in Patients Undergoing Endovascular Aneurysm Repair
Authors: Patrizia Lo Sapio, Emiliano Chisci, Anna Maria Gori, Cristina Botteri, Nicola Troisi, Filippo Turini, Azzurra Guidotti, Eugenio Romano, Pierfrancesco Frosini, Enrico Barbanti, Clara Pigozzi, Stefano Michelagnoli, Rossella Marcucci
Journal: Circulation (2018)

Introduction: The 2017 ACC/AHA guidelines on the diagnosis of hypertension recommend treatment for patients on stage 1 of hypertension ( target ≥130/80 mmHg) with high cardiovascular risk. Few data...
THU0129 Unavoidable and modifiable risk factors for ischaemic heart disease (IHD) in rheumatoid arthritis (RA)
Authors: NX Erb, MJ Banks, IF Rowe, GD Kitas
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> IHD is the commonest single cause of death in RA.<sup>1</sup> Having RA is an independent risk factor for the development of IHD.<sup>2</sup> Classical risk factors are also important, contributing a baseline risk as they do in the general population. The baseline risk can be calculated using general population data,<sup>3</sup> and its modifiable component may be an important therapeutic target in RA. <h3>Objectives</h3> To identify the absolute baseline risk in a hospital RA population, determine its modifiable and non-modifiable components, and assess the relative contribution of each of the modifiable risk factors. <h3>Methods</h3> 63 random hospital outpatients with RA (40 females, 23 males, age: 59.75 (10.58) years) were assessed using the Cardiac Risk Analysis Body Manager Version 1.24 Software. Absolute risk value was calculated for each individual; this was subdivided into modifiable risk (calculated from weight, systolic BP, total cholesterol, smoking and exercise habits) and non-modifiable risk (calculated from gender, age and family history of IHD). <h3>Results</h3> Total population mean (SD): Systolic BP: 145.95(22.54) mmHg; Total Cholesterol: 5.73(1.01) mmol/l; BMI: 28.12(4.07); smokers: 19.05% [male: 21.74% vs. female 17.5%; p &lt; 0.01]. 22.2% of patients (males &gt;females, p &lt; 0.05) were at high absolute risk, 68.3% at moderate risk and 10% at average or low risk of having a major cardiovascular event in the next 6–8 years. The mean absolute risk for the group was moderate 30.89(5.03)%. Most of the absolute risk was modifiable [60.89(9.83)%] the remaining 39.17(9.78)% being non-modifiable. The largest contributors to the modifiable component were exercise 36.68(9.28)% and weight 24.24(9.68)%; Systolic BP, total cholesterol and smoking contributed much less [18.44(7.61)%, 16.32(10.34)%, and 4.02(9.42)% respectively]. <h3>Conclusion</h3> 90% of hospital RA patients have a moderate or high baseline cardiovascular risk to develop a major event in the next 6–8 years. Two thirds of this risk is modifiable, and two thirds of the modifiable component is due to reduced exercise and increased weight. We suggest that all RA patients should have their classical IHD risk factors assessed and appropriately targeted in the routine clinical setting. <h3>References</h3> Wolfe F, Mitchell DM, Sibley JT, <i>et al</i>. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94 Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent risk factor ischaemic heart disease. Arthritis Rheum. 2000;43(9):S385 Liao Y, McGee DL, Cooper RS, Sutkowski MB. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999;137:837–45
SP0122 Planning surgery for patients with rheumatic diseases
Authors: P Thomas
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> Patients with rheumatic diseases often present with several problems amenable to orthopaedic surgical treatment. These problems are usually progressing at different rates, and the best surgical treatment for one may conflict with the treatment of the others. Each patient presents with a unique set of problems, but some patterns tend to emerge. The crucial question is; what to do and when? I will be discussing how to make this decision logically in patients in whom several orthopaedic problems co-exist.
Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience
Authors: Audrey M. Sigmund, Justin Jiang, Qiuhong Zhao, Patrick Elder, Don M. Benson, Ashley Rosko, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Basem M. William, Alice S. Mims, Hannah Choe, Karilyn Larkin, Jonathan E Brammer, Sarah A Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera, Nidhi Sharma
Journal: Blood (2020)
Erratum. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017;40:1010–1016
Authors: Rose A. Gubitosi-Klug, Barbara H. Braffett, Neil H. White, Robert S. Sherwin, F. John Service, John M. Lachin, William V. Tamborlane
Journal: Diabetes Care (2020)

The authors report that there was an error in the abstract of the above-referenced article. The rates of severe hypoglycemia in the former intensive treatment group and conventional treatment group of the Diabetes …
Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects
Authors: Reona Sakemura, Elizabeth C. Eckert, Sydney B. Crotts, Linh Pham, Elizabeth L. Siegler, Michelle J. Cox, Erin E. Tapper, Mehrdad Hefazi, Claudia Manriquez Roman, Kendall J. Schick, Ismail Can, Evandro D. Bezerra, Lionel Kankeu Fonkoua, Paulina Horvei, Michael W. Ruff, Susan L. Slager, Sameer A. Parikh, Neil E. Kay, Kah-Whye Peng, Stephen J. Russell, Saad S. Kenderian
Journal: Blood (2020)
Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma
Authors: Matthew J Frigault, Michael R. Bishop, Elizabeth K. O'Donnell, Noopur S. Raje, Allegra Mondillo, Daniella Cook, Heather Daley, Carissa Mangus, David W LeFleur, Janine M Buonato, Justin P Edwards, Laura K Richman, Maria T Polianova, Maria Sabatino, Scott Currence, Angela Shen, Travis Quigley, Marcela V. Maus
Journal: Blood (2020)
Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’
Authors: Ran Cui, Qiang Tong, Zhi-Yong Chen, Miao Chen, Sheng-Ming Dai
Journal: Annals of the Rheumatic Diseases (2020)

We read with great interest the published paper by Xia et al 1 which provided an in-depth analysis regarding the relationship between psoriasis, psoriatic arthritis (PsA) and osteoporosis. By comprehensively analysing the datasets from three Genome-Wide Association Studies and UK Biobank, the authors concluded that the association between PsA and estimated bone mineral density (eBMD)/osteoporosis/fracture was not genetically determined but secondary (eg, treatment with methotrexate or ciclosporin). Although the conclusion was drawn based on very stringent confounders controlling, there are a few points in this study that are worth mentioning.

First, typically, many background characteristics should be controlled in an observational study, especially with large datasets. In association analysis part, only seven confounders (ie, age, height, weight, smoking, drinking, regular physical …
Abstract PO-105: The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis
Authors: Beate Heissig, Yousef Salama, Taro Osada, Yuko Tsuda, Satoshi Takahashi, Koichi Hattori
Journal: Cancer Research (2020)

Abstract The multifunctional endocytic receptor low-density lipoprotein receptor-related protein (LRP)1 has recently been identified as a hub within a biomarker network for multicancer clinical outcome prediction. The mechanismhowLRP1 modulates cancer progression is poorly understood. In this studywe found that LRP1 and one of its ligands, tissue plasminogen activator (tPA), are expressed inmelanoma cells and control melanoma growth and lung metastasis in vivo. Mechanistic studies were performed on 2 melanoma cancer cell lines, B16F10 and the B16F1 cells, both of which formprimary melanoma tumors, but only B16F10 cells metastasize to the lungs. Tumor-, but not niche cell–derived tPA, enhanced melanoma cell proliferation in tPA2/2 mice. Gain-of-function experiments revealed that melanoma LRP1 is critical for tumor growth, recruitment of mesenchymal stem cells into the tumor bed, and metastasis. Melanoma LRP1 was found to enhance ERK activation, resulting in increased matrix metal-loproteinase (MMP)-9 RNA, protein, and secreted activity, a well-known modulator of melanoma metastasis. Restoration of LRP1 and tPA in the less aggressive, poorly metastatic B16F1 tumor cells enhanced tumor cell proliferation and led to massive lung metastasis in murine tumor models. Antimelanoma drug treatment induced tPA and LRP1 expression. tPA or LRP1 knockdown enhanced chemosensitivity in melanoma cells. Our results identify the tPA-LRP1 pathway as a key switch that drives melanoma progression, in part by modulating the cellular composition and proteolytic makeup of the tumor niche. Targeting this pathway may be a novel treatment strategy in combination treatments for melanoma. Citation Format: Beate Heissig, Yousef Salama, Taro Osada, Yuko Tsuda, Satoshi Takahashi, Koichi Hattori. The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-105.
Abstract PO-039: Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer
Authors: Christopher Jon Hanley, Sara Waise, Parker Rachel, Maria-Antoinette Lopez, Julian Taylor, Lucy Kimbley, Jonathon West, Christian Ottensmeier, Mat Rose-Zerilli, Gareth Thomas
Journal: Cancer Research (2020)

Abstract In this study we set out to define the prominent fibroblast subpopulations found in human non-small cell lung cancer. Fibroblasts are functionally heterogeneous cells, capable of promoting and suppressing tumor progression. Across cancer types, the extent and cause of this phenotypic diversity remains unknown. We used single-cell RNA sequencing and multiplexed immunohistochemistry to examine fibroblast heterogeneity in human lung and non-small cell lung cancer (NSCLC) samples. We then performed in silico and in vitro analyses to examine the molecular mechanisms regulating fibroblast phenotypes. Single-cell RNA sequencing identified seven fibroblast subpopulations: including inflammatory fibroblasts and myofibroblasts (representing terminal differentiation states), quiescent fibroblasts, proto-myofibroblasts (x2) and proto-inflammatory fibroblasts (x2). Multiplex immunohistochemistry showed that these fibroblast subpopulations were variably distributed throughout tissues but accumulated at discrete niches associated with differentiation status. Bioinformatics analyses suggested TGF-β1 and IL-1 as key regulators of myofibroblastic and inflammatory differentiation respectively. However, in vitro analyses showed that whilst TGF-β1 stimulation in combination with increased tissue tension could induce myofibroblast marker expression, it failed to fully re-capitulate ex-vivo¬ phenotypes. Similarly, IL-1β treatment only induced upregulation of a subset of inflammatory fibroblast marker genes. In silico modelling of ligand-receptor signaling identified additional pathways and cell interactions likely to be involved in fibroblast activation. This highlighted a potential role for IL-11 and IL-6 (among other ligands) in myofibroblast and inflammatory fibroblast activation respectively. This analysis provides valuable insight into fibroblast subtypes and differentiation mechanisms in NSCLC. Citation Format: Christopher Jon Hanley, Sara Waise, Parker Rachel, Maria-Antoinette Lopez, Julian Taylor, Lucy Kimbley, Jonathon West, Christian Ottensmeier, Mat Rose-Zerilli, Gareth Thomas. Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-039.
A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma
Authors: Iolanda Donatella Vincelli, Patrizia Cufari, Carmelo Toscano, Al Sayyad Said, Mauro Campello, Giuseppina Caruso, Maria Grazia D'Errigo, Irene Bova, Corrado Mammi', Stefania Ciolli, Massimo Martino, Bianca Oliva, Cristina Garreffa, Bruno Martino
Journal: Blood (2020)
CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells
Authors: Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, C.L. Beach, Keshava Kumar, Anjan Thakurta, Daniel Lopes de Menezes
Journal: Blood (2020)
Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia
Authors: Jia-Ning Zhang, Peng Zhao, Kaiyan Liu, Ming Hou, Yanqiu Han, Jian-Da Hu, Ze-Ping Zhou, Xin Wang, Ru Feng, Lin-Hua Yang, He-Bing Zhou, Tie-nan Zhu, Ye Jun Wu, Xiao-Hui Zhang
Journal: Blood (2020)
Bone and joint enhancement filtering: Application to proximal femur segmentation from uncalibrated computed tomography datasets
Authors: Bryce A. Besler, Andrew S. Michalski, Michael T. Kuczynski, Aleena Abid, Nils D. Forkert, Steven K. Boyd
Journal: Medical Image Analysis (2020)

Methods for reliable femur segmentation enable the execution of quality retrospective studies and building of robust screening tools for bone and joint disease. An enhance-and-segment pipeline is proposed for proximal femur segmentation from computed tomography datasets. The filter is based on a scale-space model of cortical bone with properties including edge localization, invariance to density calibration, rotation invariance, and stability to noise. The filter is integrated with a graph cut segmentation technique guided through user provided sparse labels for rapid segmentation. Analysis is performed on 20 independent femurs. Rater proximal femur segmentation agreement was 0.21 mm (average surface distance), 0.98 (Dice similarity coefficient), and 2.34 mm (Hausdorff distance). Manual segmentation added considerable variability to measured failure load and volume (CVRMS > 5%) but not density. The proposed algorithm considerably improved inter-rater reproducibility for all three outcomes (CVRMS < 0.5%). The algorithm localized the periosteal surface accurately compared to manual segmentation but with a slight bias towards a smaller volume. Hessian-based filtering and graph cut segmentation localizes the periosteal surface of the proximal femur with comparable accuracy and improved precision compared to manual segmentation.
Peripherally Inserted Central Catheter (PICC) Related Deep Venous Thrombosis: A Retrospective Cohort Study on Incidence and Risk Factors in a Single Center
Authors: June Iriondo, Oihane Iñarra, Beatriz Sarriegui, Nekane Sanz, Maialen Lasa, Maria Aranzazu Aguirre, Cristina Sarasqueta, Jesus Blanco, Maria Rua, Gabriela Yurrita, Sergio Martin, Jennifer Gomez, Maite Centeno, Maria Araiz, Camino Del Rio, Izaskun Ceberio
Journal: Blood (2020)
Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation
Authors: Daniela Pais Ferreira, Joana Gomes Silva, Tania Wyss, Silvia A. Fuertes Marraco, Léonardo Scarpellino, Mélanie Charmoy, Roeltje Maas, Imran Siddiqui, Li Tang, Johanna A. Joyce, Mauro Delorenzi, Sanjiv A. Luther, Daniel E. Speiser, Werner Held
Journal: Immunity (2020)
Prognostic Factors for North American Adult T Cell Leukemia Lymphoma: Defining Risk Groups Using a Four-Point Score Prognostic System
Authors: Shafia Rahman, Alvaro Alvarez Soto, Lindor Qunaj, Kenny Ye, Kith Pradhan, Astha Thakkar, Zhu Cui, Michal Kasher Meron, Angelica D'Aiello, Amanda Lombardo, Jennat Mustafa, Fariha Khatun, Kailyn Gillick, Felisha Joseph, Anjali Naik, Alyssa De Castro, Ulrich G. Steidl, Hao Wang, Xiaoxin Ren, Xingxing Zang, Olga Derman, Kira Gritsman, Noah Kornblum, Aditi Shastri, Ioannis Mantzaris, Mendel Goldfinger, Ira Braunschweig, B. Hilda Ye, Amit Verma, Murali Janakiram, Urvi A Shah, R. Alejandro Sica
Journal: Blood (2020)
Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012-2017 Medicare Data
Authors: Ruben Niesvizky, Zoe Clancy, Ronda Copher, Ryan B. Thomas, Cynthia Z. Qi, Zheng-Yi Zhou, Miriam L. Zichlin, Sarah H. Koenigsberg, James E. Signorovitch
Journal: Blood (2020)
The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma
Authors: Hadiyah Y. Audil, Joselle Cook, Patricia Greipp, Prashant Kapoor, Linda B Baughn, Angela Dispenzieri, Morie A Gertz, Francis K. Buadi, Martha Q. Lacy, David Dingli, Amie Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Eli Muchtar, Mustaqeem A. Siddiqui, Wilson I Gonsalves, Yi L. Hwa, Nelson Leung, Ronald S. Go, Yi Lin, Taxiarchis Kourelis, Rahma M Warsame, John A. Lust, Robert A. Kyle, Rhett P. Ketterling, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood (2020)
Abstract 15249: Brain Angiotensin II Type 1 Receptor-Induced Disruption of Glymphatic System Increased Sympathetic Nerve Activity in Ischemic Heart Failure
Authors: Takuya Kishi
Journal: Circulation (2019)

Introduction: Abnormal sympathoexcitation is a major worsening factor in myocardial infarction (MI)-induced heart failure, and it has already demonstrated that angiotensin II receptor type 1 (AT1R)...
Interferon Induction By HbS, SERINC5 Upregulation and Reduction of HIV-1 <i>Nef</i> and AP2 Contribute to HIV-1 Restriction in Sickle Cell Disease
Authors: Namita Kumari, Marina Jerebtsova, Songping Wang, Sharmin Diaz, Sergei Nekhai
Journal: Blood (2020)
AB0056 CUTANEOUS ADVERSE EFFECTS WITH BIOLOGIC AGENTS
Authors: Bilal Bengana, Abdenour Boukabous, Naima Bahaz, Salima Lefkir
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Biologic agents (BA) are designed to treat chronic inflammatory diseases (CID), however, the adverse effects inherent with these drugs are more and more encountered. Among them are dermatological manifestations : infections, allergic reactions or even skin cancers, which sometimes require stopping treatment temporarily or permanently. <h3>Objectives</h3> The goal of this work consists to identify the cutaneous manifestations (CA) that have been reported to the most commonly used biologics in CID. <h3>Methods</h3> It's a prospective study in patients received in day hospital and treated with BA for CID during a period of 9 months (October 2017 - June 2018), we recorded all the data on CA after a complete dermatological examination, nor forgetting that we appreciated the phototype of the patients, the level of exposure to the sun and means of photoprotection. <h3>Results</h3> We collected the data of 68 patients under BA for the study (Adalimumab = 21, Etanercept= 17, Tocilizumab = 12, Infliximab = 7, Rituximab = 11) with a clear female predominance 59.4%, the mean age was 39 years. 37 (54%) had cutaneous manifestations, the main CA occurred with TNFα inhibitors 21/68 (30%), with more often skin infections. The other CA encountered were cutaneous rashes and allergic reactions, appearance of psoriasis or eczema and injection site reactions, we didnt cross any skin cancer. <h3>Conclusion</h3> Cutaneous manifestations remain frequent and relatively benign with BA. This work confirms the importance of education and dermatological monitoring of patients treated with biologic drugs in the CID. This prospective study needs to be completed over a longer period especially to screen any skin cancer. <h3>Disclosure of Interests</h3> None declared
Time for <i>BRCA</i> Testing Among Women 65 Years or Older in the United States
Authors: Robert Charles Burton
Journal: JAMA Network Open (2020)

Fangjian Guo, MD, PhD; Matthew Scholl, BS; Erika L. Fuchs, PhD, MPH; Rebeca Wong, PhD; Yong-Fang Kuo, PhD; Abbey B. Berenson, MD, PhD
Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study
Authors: Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Alexandros Leonidakis, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos
Journal: Blood (2020)
Protecting health in dry cities: considerations for policy makers
Authors: Howard Frumkin, Maitreyi Bordia Das, Maya Negev, Briony C Rogers, Roberto Bertollini, Carlos Dora, Sonalde Desai
Journal: BMJ (2020)

Water has always been essential for cities to survive and thrive.The earliest cities, from 4000 BC, were founded near water sources.Conversely, water scarcity might have contributed to the demise of ancient cities such as Tikal in present day Guatemala and Angkor in present day Cambodia. 1 2Water deprivation was also used as a weapon in ancient times; when Sennacherib of Assyria ransacked Babylon in 689 BC, he destroyed the city's water supply. 3y cities present complex challenges in a dynamic world.The supply of water in many cities will increasingly fall short of demand, with diverse and potentially severe effects on health.In a world of pervasive inequalities, water scarcity is likely to hit the most vulnerable hardest.The challenge of achieving health in dry cities is intensified in the setting of resource scarcity, state and societal fragility, and weak institutions.The inter-relation between human health and the environment needs to be central to planning and management of both water and health systems.Promoting health and wellbeing in dry cities is essential to achieving the sustainable development goals.Innovation will be key to progress; it requires foresight, strong institutions, and action from many people.Today's global population is increasingly urban, and the world is increasingly hot, with dry regions becoming drier.Dry cities have scarce water relative to demand.An estimated 150 million people live in cities that have perennial water shortage. 4me cities are dry because of their location in arid environments, with low levels of fresh water, precipitation, or both.In the year 2000 about 27% of the world's urban area was in drylands. 4Many of the world's most water stressed countries are in the Middle East and North Africa (box 1).Doha, Abu Dhabi, and Dubai in the Gulf region, and desert cities, including Cairo (Egypt) and Windhoek (Namibia), Antofagasta (Chile), Trujillo (Peru), Phoenix, and Las Vegas (United States) are widely recognized as "dry cities."
CD56briCD27+CD11b+/- NK Cells Mediated Remission of Agvhd Via Immunoregulation
Authors: Ming Ni, Peng Zhao, Qian Kang, Mei Zhao, Min Liu, Fengqi Zhang, Shisi Huang, Dan Ma, Yaming Zhang, Jiangyuan Zhao, Jishi Wang
Journal: Blood (2020)
The cat is out of the bag – point-of-care testing (POCT) is here to stay
Authors: Nick Phin, Susan M Poutanen
Journal: Eurosurveillance (2020)

Preview this article: The cat is out of the bag – point-of-care testing (POCT) is here to stay, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/25/44/eurosurv-25-44-1-1.gif